StockMacro
Company, fund or insider

Help

Menu

Standard BioTools

LAB on XNAS, Standard BioTools Inc.

Measures activity, not value. Not investment advice.

Latest quarter (Jul 2026)

-0.9%

+0.8 pts vs its 3-year median

Sharp changes

8

quarterly revenue change, quarterly capital spending jump

Window

What usually follows Revenue growth was not followed by a clear share-price difference over the next 6 months. No relationship found How we measured it

Median revenue growth on a year earlier: -0.9% in the quarter from 1 Jul 2026 (3-year median -1.6%)

10-Q and 10-K figures, by the quarter they describe. Dashed: 3-year median.

See the numbers
Quarter of Jul 2026: -0.9%
Quarter of Apr 2026: -7.6%
Quarter of Jan 2026: -48%
Quarter of Jul 2025: -57%
Quarter of Apr 2025: -42%
Quarter of Jan 2025: -10%
Quarter of Oct 2024: +66%
Quarter of Jul 2024: +77%
Quarter of Apr 2024: +34%
Quarter of Jan 2024: +81%
Quarter of Oct 2023: +4.3%
Quarter of Jul 2023: -1.1%
Quarter of Apr 2023: +47%
Quarter of Jan 2023: -5.2%
Quarter of Oct 2022: -29%
Quarter of Jul 2022: -10%
Quarter of Apr 2022: -39%
Quarter of Jan 2022: -19%
Quarter of Oct 2021: -14%
Quarter of Jul 2021: -28%
Quarter of Apr 2021: +19%
Quarter of Jan 2021: +19%
Quarter of Oct 2020: +38%
Quarter of Jul 2020: +50%
Quarter of Apr 2020: -7.6%
Quarter of Jan 2020: -8.3%
Quarter of Oct 2019: +0.4%
Quarter of Jul 2019: -8.5%
Quarter of Apr 2019: +6.7%
Quarter of Jan 2019: +19%
Quarter of Oct 2018: +17%
Quarter of Jul 2018: +17%
Quarter of Apr 2018: +11%
Quarter of Jan 2018: -1.1%
Quarter of Oct 2017: +11%

What the numbers say

  • Median revenue growth on a year earlier: -0.9% in the quarter from 1 Jul 2026 (3-year median -1.6%); the most since Oct 2024.
  • 8 sharp changes in all loaded history (quarterly revenue change, quarterly capital spending jump).
  • Median growth on a year earlier, latest complete quarter: the largest is Deferred revenue, -72%.
Median growth on a year earlier, latest complete quarter: the largest is Deferred revenue, -72%
See the numbers
Deferred revenue-72%
Inventory-31%
Contracted backlog-8.9%
Revenue-0.9%

Every measure from this source

5 years, by the period each figure describes

Revenue (quarter). $60.6M in the last 12 months, -53% on the year before.
Capital spending (quarter). $2.3M in the last 12 months, -82% on the year before.
R&D expense (quarter). $6.2M in the last 12 months, -74% on the year before.
Inventory (quarter end). $17.6M in the latest period, -31% on a year earlier.
Deferred revenue (quarter end). $11.9M in the latest period, -72% on a year earlier.
Contracted backlog (RPO). $16.7M in the latest period, -8.9% on a year earlier.
Revenue (fiscal year). $85.3M in the last 12 months, -51% on the year before.
Capital spending (fiscal year). $8.3M in the last 12 months, -0.6% on the year before.
R&D expense (fiscal year). $26.0M in the last 12 months, -58% on the year before.
Shares outstanding. 392.6M in the latest period, +2.8% on a year earlier.

Sharp changes

8 in all loaded history, strongest first

Standard BioTools reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year.

Quarterly revenue change, became public on 14 May 2024

Same quarter last year: $25.1M; its normal quarter is $26.1M.

See the evidence
This period
$45.5M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$26.1M
Typical spread (median absolute deviation)
$951K
How far from its usual level
+7.5
Same quarter last year
$25.1M
History used
5,023 days
2022-03-31: $26.5M2022-06-30: $18.8M2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M
the quarter ended 31 Mar 20248 earlier quartersnormal: $26.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Standard BioTools reported revenue of $45.0M for the quarter ended 30 Sep 2024, 1.8× the same quarter last year.

Quarterly revenue change, became public on 12 Nov 2024

Same quarter last year: $25.4M; its normal quarter is $27.3M.

See the evidence
This period
$45.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$27.3M
Typical spread (median absolute deviation)
$1.8M
How far from its usual level
+6.4
Same quarter last year
$25.4M
History used
5,206 days
2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M2024-09-30: $45.0M
the quarter ended 30 Sep 20248 earlier quartersnormal: $27.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Standard BioTools reported revenue of $46.7M for the quarter ended 31 Dec 2024, 1.7× the same quarter last year.

Quarterly revenue change, became public on 18 Mar 2025

Same quarter last year: $28.2M; its normal quarter is $27.9M.

See the evidence
This period
$46.7M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$27.9M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+4.7
Same quarter last year
$28.2M
History used
5,298 days
2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M2024-09-30: $45.0M2024-12-31: $46.7M
the quarter ended 31 Dec 20248 earlier quartersnormal: $27.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Standard BioTools reported revenue of $37.2M for the quarter ended 30 Jun 2024, 1.3× the same quarter last year.

Quarterly revenue change, became public on 13 Aug 2024

Same quarter last year: $27.7M; its normal quarter is $26.3M.

See the evidence
This period
$37.2M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$26.3M
Typical spread (median absolute deviation)
$1.3M
How far from its usual level
+4.1
Same quarter last year
$27.7M
History used
5,114 days
2022-06-30: $18.8M2022-09-30: $25.6M2022-12-31: $27.0M2023-03-31: $25.1M2023-06-30: $27.7M2023-09-30: $25.4M2023-12-31: $28.2M2024-03-31: $45.5M2024-06-30: $37.2M
the quarter ended 30 Jun 20248 earlier quartersnormal: $26.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Standard BioTools reported revenue of $39.9M for the quarter ended 30 Sep 2020, 1.5× the same quarter last year.

Quarterly revenue change, became public on 10 Nov 2020

Same quarter last year: $26.5M; its normal quarter is $28.6M.

See the evidence
This period
$39.9M (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
$28.6M
Typical spread (median absolute deviation)
$1.8M
How far from its usual level
+3.9
Same quarter last year
$26.5M
History used
3,745 days
2018-09-30: $29.0M2018-12-31: $32.3M2019-03-31: $30.1M2019-06-30: $28.2M2019-09-30: $26.5M2019-12-31: $32.4M2020-03-31: $27.6M2020-06-30: $26.1M2020-09-30: $39.9M
the quarter ended 30 Sep 20208 earlier quartersnormal: $28.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Standard BioTools reported revenue of $44.6M for the quarter ended 31 Dec 2020, 1.4× the same quarter last year.

Quarterly revenue change, became public on 2 Mar 2021

Same quarter last year: $32.4M; its normal quarter is $29.2M.

See the evidence
This period
$44.6M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$29.2M
Typical spread (median absolute deviation)
$2.9M
How far from its usual level
+3.6
Same quarter last year
$32.4M
History used
3,837 days
2018-12-31: $32.3M2019-03-31: $30.1M2019-06-30: $28.2M2019-09-30: $26.5M2019-12-31: $32.4M2020-03-31: $27.6M2020-06-30: $26.1M2020-09-30: $39.9M2020-12-31: $44.6M
the quarter ended 31 Dec 20208 earlier quartersnormal: $29.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

The records

One row per company, data through 1 Nov 2026

Showing 1 to 1 of 1.
CompanySectorLatest quartervs year before
Standard BioToolsHealth Care$19.4M